U.S. v. Chowdhury

• Decision Date: 22 February 2011
• Docket Number: Docket No. 09–3442–cr.
• Citation: 639 F.3d 583
• Parties: UNITED STATES of America, Appellee,v.Nizamuddin CHOWDHURY, Defendant–Appellant.*
• Court: U.S. Court of Appeals — Second Circuit

639 F.3d 583

UNITED STATES of America, Appellee,

v.Nizamuddin CHOWDHURY, Defendant–Appellant.*

Docket No. 09–3442–cr.

United States Court of Appeals, Second Circuit.

Argued: Feb. 17, 2011.Decided: Feb. 22, 2011.

Gennaro D. Calabrese, Kindlon Shanks & Associates, Albany, NY, for Defendant–Appellant Nizamuddin Chowdhury.Paul D. Silver, Assistant United States Attorney (Richard S. Hartunian, United States Attorney, on the brief; and Daniel C. Gardner, Assistant United States Attorney, of counsel), United States Attorney's Office for the Northern District of New York, Albany, NY, for Appellee United States of America.Before: CABRANES, CHIN, Circuit Judges, and CROTTY, District Judge. ^**PER CURIAM:

The question presented is whether the United States District Court for the Northern District of New York (Glenn T. Suddaby, Judge ) engaged in clearly erroneous fact-finding that led to a procedurally unreasonable sentence when it determined that the controlled substance referenced in the United States Sentencing Guidelines that is most closely related to a mixture of 1–Benzylpiperazine (“BZP”) and 3–Triflouromethylphenyl (“TFMPP”) is 3, 4–Methylenedioxymethamphetamine (“MDMA”), or ecstasy. We hold that the District Court did not err, much clearly err, and therefore affirm.

BACKGROUND

The facts of this case are not in dispute. In November 2008, approximately 28,000 yellow pills were found in defendant-appellant Nizamuddin Chowdhury's car when he was stopped at a U.S. Customs and Border Protection (CBP) checkpoint in upstate New York. The pills, which tested positive for MDMA at the checkpoint, were later verified at a laboratory to contain a combination of BZP and TFMPP. In February 2009, Chowdhury pleaded guilty to one count of possession with intent to distribute approximately 8.475 kilograms of BZP in violation of 21 U.S.C. § 846.

Because BZP is a “controlled substance that is not specifically referenced” in the Guidelines, the United States Probation Office calculated Chowdhury's base offense level by using the “the marijuana equivalent of the most closely related controlled substance referenced in” the Guidelines. U.S.S.G. § 2D1.1, cmt. n. 5. The marijuana equivalency for 8.475 kilograms of MDMA translates into a base offense level of 34.¹ The Probation Office reduced the offense level by 2 levels pursuant to the “safety valve” provision under U.S.S.G. § 5C1.2 and 3 more levels for Chowdhury's “acceptance of responsibility” pursuant to U.S.S.G. § 3E1.1 (a). The final offense level was therefore 29, which, with a criminal history category of I, rendered the Guidelines range 87–108 months.

At sentencing, Chowdhury argued that the use of MDMA as a substitute for BZP–TFMPP was error. He argued that because BZP is ten to twenty times less potent than MDMA, and more similar to amphetamine, the District Court should use amphetamine as the most closely related substitute. In response, the government argued that—according to the Forensic Laboratory in New York City of the Drug Enforcement Administration (“DEA”)—“BZP is mixed with TFMPP for the specific purpose of mimicking the effects of MDMA”; that “the mixture of the two chemicals together causes an effect on the central nervous system similar to MDMA”; and that the combination of BZP and TFMPP is “sold by drug traffickers as MDMA at the same price.” Rebuttal Sentencing Memorandum of the United States 6. The District Court concluded that “it's pretty clear that when BZP [is] combined with TFMPP, it is closest to [MDMA], ecstasy.” Transcript of Sentencing Proceeding at 15, United States v. Chowdhury, 08–cr–710 (N.D.N.Y. July 31, 2009). The District Court therefore “credited” the Probation Office's calculation of the Guideline range, id., and sentenced Chowdhury within the Guideline range, principally to a 96–month term of imprisonment. Chowdhury filed a timely notice of appeal.

DISCUSSION

[3] It is well established that we review a criminal sentence for “ ‘unreasonableness,’ ” which “amounts to review for abuse of discretion.” United States v. Cavera, 550 F.3d 180, 187 (2d Cir.2008) (in banc) (quoting United States v. Booker, 543 U.S. 220, 245, 125 S.Ct. 738, 160 L.Ed.2d 621 (2005)). “Reasonableness review requires an examination of the length of the sentence (substantive reasonableness) as well as the procedure employed in arriving at the sentence (procedural reasonableness).” United States v. Johnson, 567 F.3d 40, 51 (2d Cir.2009). “Procedural error includes, among other things, selecting a sentence based on clearly erroneous facts.” United States v. DeSilva, 613 F.3d 352, 356 (2d Cir.2010) (quotation marks omitted). “[A] finding is ‘clearly erroneous' when although there is evidence to support it, the reviewing court ... is left with the definite and firm conviction that a mistake has been committed.” Anderson v. Bessemer City, 470 U.S. 564, 573, 105 S.Ct. 1504, 84 L.Ed.2d 518 (1985) (quotation marks omitted).

Chowdhury contends that the District Court clearly erred when it held that—for the purpose of calculating his guideline sentencing range—the controlled substance referenced in the Guidelines that is most closely related to a mixture of BZP and TFMPP is MDMA. He argues that, because it was clear error for the District Court to use MDMA, the District Court misapplied the Guidelines and his sentence is therefore procedurally unreasonable. We disagree. The Sentencing Guidelines specify that “[i]n determining the most closely related controlled substance” for the purposes of § 2D1.1, the Court must take into account “to the extent practicable”:

(A) Whether the controlled substance not referenced in this guideline has a chemical structure that is substantially similar to a controlled substance referenced in this guideline.

(B) Whether the controlled substance not referenced in this guideline has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance referenced in this guideline.

(C) Whether a lesser or greater quantity of the controlled substance not referenced in this guideline is needed to produce a substantially similar effect on the central nervous system as a controlled substance referenced in this guideline.

Id., cmt. n. 5.

It is clear from the record below that the District Court carefully considered the statutory factors. It relied on the DEA's determination that BZP and TFMPP are used in combination precisely because the mixture “mimic[s] the effects” of MDMA on the central nervous system. See Brief of the United States 13 (citing National Forensic Laboratory Information Midyear Report 2003 at 14, available at http:// www. deadiversion. usdoj/ gov/ nflis/ 2003 midyear. pdf (last visited on Dec. 12, 2010)); see also Microgram Bulletin—Intelligence Alert, Drug Enforcement Administration, Office of Forensic Sciences (December 2008), available at http:// www. justice. gov/ dea/ programs/ forensic scimicrogram/ mg 1208/ mg 1208. html (last visited on Jan. 29, 2011). The...